Literature DB >> 17569107

Pharmacokinetics of methylprednisolone after intravenous and intramuscular administration in rats.

Anasuya Hazra1, Nancy Pyszczynski, Debra C DuBois, Richard R Almon, William J Jusko.   

Abstract

Methylprednisolone (MPL) pharmacokinetics was examined in adrenalectomized (ADX) and normal rats to assess the feasibility of intramuscular (i.m.) dosing for use in pharmacodynamic studies. Several study phases were pursued. Parallel group studies were performed in normal and ADX rats given 50 mg/kg MPL (i.v. or i.m.) and blood samples were collected up to 6 h. Data from studies where normal rats were dosed with 50 mg/kg MPL i.m. and killed over either 6 or 96 h were combined to determine muscle site and plasma MPL concentrations. Lastly, ADX rats were dosed with 50 mg/kg MPL i.m. and killed over 18 h to assess hepatic tyrosine aminotransferase (TAT) dynamics. MPL exhibited bi-exponential kinetics after i.v. dosing with a terminal slope of 2.1 h(-1). The i.m. drug was absorbed slowly with two first-order absorption rate constants, 1.26 and 0.219 h(-1) indicating flip-flop kinetics with overall 50% bioavailability. The kinetics of MPL at the injection site exhibited slow, dual absorption rates. Although i.m. MPL showed lower bioavailability compared with other corticosteroids in rats, TAT dynamics revealed similar i.m. and i.v. response profiles. The more convenient intramuscular dosing can replace the i.v. route without causing marked differences in pharmacodynamics.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17569107      PMCID: PMC4181331          DOI: 10.1002/bdd.551

Source DB:  PubMed          Journal:  Biopharm Drug Dispos        ISSN: 0142-2782            Impact factor:   1.627


  32 in total

1.  A priori prediction of tissue:plasma partition coefficients of drugs to facilitate the use of physiologically-based pharmacokinetic models in drug discovery.

Authors:  P Poulin; F P Theil
Journal:  J Pharm Sci       Date:  2000-01       Impact factor: 3.534

2.  Pharmacogenomic responses of rat liver to methylprednisolone: an approach to mining a rich microarray time series.

Authors:  Richard R Almon; Debra C Dubois; Jin Y Jin; William J Jusko
Journal:  AAPS J       Date:  2005-08-18       Impact factor: 4.009

3.  Stability of dexamethasone sodium phosphate in rat plasma.

Authors:  Mahesh N Samtani; William J Jusko
Journal:  Int J Pharm       Date:  2005-09-14       Impact factor: 5.875

4.  Pharmacodynamics and pharmacogenomics of methylprednisolone during 7-day infusions in rats.

Authors:  Rohini Ramakrishnan; Debra C DuBois; Richard R Almon; Nancy A Pyszczynski; William J Jusko
Journal:  J Pharmacol Exp Ther       Date:  2002-01       Impact factor: 4.030

5.  Testing for the equality of area under the curves when using destructive measurement techniques.

Authors:  A J Bailer
Journal:  J Pharmacokinet Biopharm       Date:  1988-06

6.  Fourth-generation model for corticosteroid pharmacodynamics: a model for methylprednisolone effects on receptor/gene-mediated glucocorticoid receptor down-regulation and tyrosine aminotransferase induction in rat liver.

Authors:  Y N Sun; D C DuBois; R R Almon; W J Jusko
Journal:  J Pharmacokinet Biopharm       Date:  1998-06

7.  Characterization of steroid hormone ester hydrolyzing enzymes in liver microsomes.

Authors:  K Hattori; M Kamio; E Nakajima; T Oshima; T Satoh; H Kitagawa
Journal:  Biochem Pharmacol       Date:  1981-08-01       Impact factor: 5.858

8.  Dose-dependence and repeated-dose studies for receptor/gene-mediated pharmacodynamics of methylprednisolone on glucocorticoid receptor down-regulation and tyrosine aminotransferase induction in rat liver.

Authors:  Y N Sun; D C DuBois; R R Almon; N A Pyszczynski; W J Jusko
Journal:  J Pharmacokinet Biopharm       Date:  1998-12

9.  Initial rate studies of hydrolysis and acyl migration in methylprednisolone 21-hemisuccinate and 17-hemisuccinate.

Authors:  B D Anderson; V Taphouse
Journal:  J Pharm Sci       Date:  1981-02       Impact factor: 3.534

10.  Fifth-generation model for corticosteroid pharmacodynamics: application to steady-state receptor down-regulation and enzyme induction patterns during seven-day continuous infusion of methylprednisolone in rats.

Authors:  Rohini Ramakrishnan; Debra C DuBois; Richard R Almon; Nancy A Pyszczynski; William J Jusko
Journal:  J Pharmacokinet Pharmacodyn       Date:  2002-02       Impact factor: 2.745

View more
  16 in total

Review 1.  Flip-flop pharmacokinetics--delivering a reversal of disposition: challenges and opportunities during drug development.

Authors:  Jaime A Yáñez; Connie M Remsberg; Casey L Sayre; M Laird Forrest; Neal M Davies
Journal:  Ther Deliv       Date:  2011-05

2.  Modeling of corticosteroid effects on hepatic low-density lipoprotein receptors and plasma lipid dynamics in rats.

Authors:  Anasuya Hazra; Nancy A Pyszczynski; Debra C DuBois; Richard R Almon; William J Jusko
Journal:  Pharm Res       Date:  2007-08-03       Impact factor: 4.200

3.  Receptor/gene/protein-mediated signaling connects methylprednisolone exposure to metabolic and immune-related pharmacodynamic actions in liver.

Authors:  Vivaswath S Ayyar; Siddharth Sukumaran; Debra C DuBois; Richard R Almon; Jun Qu; William J Jusko
Journal:  J Pharmacokinet Pharmacodyn       Date:  2018-04-27       Impact factor: 2.745

4.  Population Pharmacokinetics of Vamorolone (VBP15) in Healthy Men and Boys With Duchenne Muscular Dystrophy.

Authors:  Panteleimon D Mavroudis; John van den Anker; Laurie S Conklin; Jesse M Damsker; Eric P Hoffman; Kanneboyina Nagaraju; Paula R Clemens; William J Jusko
Journal:  J Clin Pharmacol       Date:  2019-02-11       Impact factor: 3.126

5.  Functional proteomic analysis of corticosteroid pharmacodynamics in rat liver: Relationship to hepatic stress, signaling, energy regulation, and drug metabolism.

Authors:  Vivaswath S Ayyar; Richard R Almon; Debra C DuBois; Siddharth Sukumaran; Jun Qu; William J Jusko
Journal:  J Proteomics       Date:  2017-03-14       Impact factor: 4.044

6.  Modeling Corticosteroid Pharmacokinetics and Pharmacodynamics, Part I: Determination and Prediction of Dexamethasone and Methylprednisolone Tissue Binding in the Rat.

Authors:  Vivaswath S Ayyar; Dawei Song; Debra C DuBois; Richard R Almon; William J Jusko
Journal:  J Pharmacol Exp Ther       Date:  2019-06-13       Impact factor: 4.030

7.  Modeling Corticosteroid Pharmacokinetics and Pharmacodynamics, Part II: Sex Differences in Methylprednisolone Pharmacokinetics and Corticosterone Suppression.

Authors:  Vivaswath S Ayyar; Debra C DuBois; Toshimichi Nakamura; Richard R Almon; William J Jusko
Journal:  J Pharmacol Exp Ther       Date:  2019-06-13       Impact factor: 4.030

8.  Mechanistic Multi-Tissue Modeling of Glucocorticoid-Induced Leucine Zipper Regulation: Integrating Circadian Gene Expression with Receptor-Mediated Corticosteroid Pharmacodynamics.

Authors:  Vivaswath S Ayyar; Debra C DuBois; Richard R Almon; William J Jusko
Journal:  J Pharmacol Exp Ther       Date:  2017-07-20       Impact factor: 4.030

9.  Modeling receptor/gene-mediated effects of corticosteroids on hepatic tyrosine aminotransferase dynamics in rats: dual regulation by endogenous and exogenous corticosteroids.

Authors:  Anasuya Hazra; Nancy Pyszczynski; Debra C DuBois; Richard R Almon; William J Jusko
Journal:  J Pharmacokinet Pharmacodyn       Date:  2007-06-26       Impact factor: 2.745

10.  Alpha-methylprednisolone conjugated cyclodextrin polymer-based nanoparticles for rheumatoid arthritis therapy.

Authors:  Jungyeon Hwang; Kathleen Rodgers; James C Oliver; Thomas Schluep
Journal:  Int J Nanomedicine       Date:  2008
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.